New drug combo shows promise in advanced cancer trial

NCT ID NCT05174585

Completed Disease control Sponsor: Jacobio Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 17 times

Summary

This early-phase study tested a new drug called JAB-BX102, given alone or with another drug (pembrolizumab), in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also looking for signs that the tumors shrank. The study is complete, but results are not yet reported.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China
Huashan Hospital

Shanghai, Shanghai Municipality, 200040, China
Hunan Cancer Hospital

Changsha, Hunan, 410013, China
Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China
The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, 233004, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450052, China

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR